Atrial Fibrillation Market Report (2022 to 2030) – Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, Agricore Inc., and Siemens AG

Pune, Oct. 28, 2022 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the global atrial fibrillation market is expected to clock US$ 2.4 billion by 2030 and to grow at a CAGR of 6.3% during the forecast period. The high prevalence of atrial fibrillation and the increasing geriatric population are the prime reason for the expansion of the market. This exclusive information is published by Growth Plus Reports in its report titled “Atrial Fibrillation Market – Global Outlook & Forecast 2022-2030”

Download PDF Brochure of Atrial Fibrillation Market Size – COVID-19 Impact and Global Analysis with Strategic Developments at: https://growthplusreports.com/inquiry/request-sample/atrial-fibrillation-market/7897

Market driver

The incidence and prevalence of atrial fibrillation (AFib) have increased by almost 33% globally over the past 20 years, with high sociodemographic indices showing the highest impact. The significant rise in AFib prevalence can be attributed to several factors, including the aging of the global population, the prolonged survival of people with cardiac conditions that increase their risk of atrial fibrillation, and the rising prevalence of AFib risk factors like hypertension and obesity in the population at risk. Atrial fibrillation is also in demand due to improvements in detection technologies and an increase in the use of electrocardiography (ECG), both in conventional clinical settings and through wearable or implantable devices with continuous AFib-detecting capabilities. Increased comorbidities such as a high body mass index, diabetes, hypertension, and chronic lung disease can further contribute to the rising acceptance of AFib.

Excerpts from ‘By End-user Segmentation’

Based on end-user, the global atrial fibrillation market has been segmented into:

• Hospitals
• Specialty Clinics
• Electrophysiology
• Others

Hospitals have seen the most revenue growth due to laser and radiofrequency catheter ablation techniques. In 2019, the novel coronavirus (COVID-19) expanded quickly across many countries and regions, significantly impacting lives and expanding the atrial fibrillation market. Additionally, the number of persons experiencing atrial fibrillation is rising due to the growing obesity problem. As a result, it is believed that increasing obesity rates are also fuelling market expansion.

Excerpts from ‘By Region Segmentation’

The global atrial fibrillation market has been segmented into:

• North America
• Europe
• Asia Pacific
• Rest of the World (RoW)

The atrial fibrillation market is anticipated to be dominated by the North American region. This is primarily due to the growing patient population in the region and the presence of important players. The United States is anticipated to dominate market expansion in the North American region. According to data from the CDC (Centre for Disease Control and Prevention), 12.1 million Americans are predicted to have atrial fibrillation by 2030. With the aging population likely to rise, it is anticipated that demand for the market under study will increase in the coming years. The development of the market under research in the United States is being accelerated by significant competitors in the industry, technological improvements, and the availability of favorable insurance policies. For instance, in July 2021, The WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device from Boston Scientific Corporation was given the green light by the US Food and Drug Administration. This device is indicated to lower the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy.

Inquiry Before Buying: https://growthplusreports.com/inquiry/before-buying/atrial-fibrillation-market/7897

Excerpts from ‘Competitive Landscape’

The market under study is fragmented and very moderately competitive. The atrial fibrillation market comprises domestic and international companies concentrating on developing innovative product launches; increased R&D activities are also monitoring the emergence of new competitors. More companies are anticipated to enter the market due to technological developments and the focus on enhancing the healthcare system, thus boosting the market growth. Some of the major players in the global atrial fibrillation market include:

• Abbott Laboratories
• Atricure Inc.
• Johnson & Johnson
• Microport Scientific Corporation
• Boston Scientific Corporation
• Biosense Webster, Inc.
• Siemens AG
• Medtronic Plc
• Koninklijke Philips N.V.
• Cardiofocus, Inc.
• Biotitic Se & Co. Kg, Inc.
• Carima, Inc.
• Ncontact, Inc.
• Agricore, Inc.

For instance, in 2020, according to CathVision, the University of Vermont Medical Center finished enrolling patients in the CathVision ECGenius System clinical evaluation study. A significant advancement in the quality of ECG signal acquisition, interpretation, and therapeutic assistance is represented by ECGenius, which aids in the accurate diagnosis and development of ablation techniques for complex arrhythmias, including such atrial fibrillation (AF).

Table of Content

1. INTRODUCTION
   1. Market Ecosystem 
   2. Timeline Under Consideration
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions       
3. PREMIUM INSIGHTS
   1. Current Market Trend (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2021) 
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL ATRIAL FIBRILLATION MARKET – ANALYSIS & FORECAST, BY TYPE
   1. Surgical
   2. Non-surgical
6. GLOBAL ATRIAL FIBRILLATION MARKET – ANALYSIS & FORECAST, BY TECHNOLOGY
   1. Radiofrequency
   2. Laser
   3. Cryotherapy
   4. Others
7. GLOBAL ATRIAL FIBRILLATION MARKET – ANALYSIS & FORECAST, BY END-USER
   1. Hospitals
   2. Specialty Clinics
   3. Electrophysiology
   4. Others

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Directly Purchase Premium Copy of Atrial Fibrillation Market Growth Report (2022-2030) at: https://growthplusreports.com/checkout?_token=tHVgidA3EwK2Dd8RaQcITKSC9EFIhXQFo0HpXoZc&report_id=7897&license=Single

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.